Hypofractionated Radiotherapy for Lung Cancer

Study summary

The purpose of this trial is to pilot reducing the duration of radiation treatment for lung cancer patients from 6 to 5 weeks using tomotherapy. Specific patient doses will be based on tumor volume being treated. Modeling has shown that increased biologically effective dose (BED) to tumors can be achieved by shortening the radiation delivery schedule and increasing the dose per fraction. This requires decreasing the total dose to hold lung toxicity constant at each dose per fraction level. This is a major paradigm shift in the treatment in this disease and is projected to result in significant improvements in patient outcome as well as a substantial cost savings.

Ask AI to explain this study

Start here

Key things to know

Main goalPrevention

This describes the study’s primary purpose.

What is being studiedradiation therapy (radiotherapy)

The study team can explain what participation involves.

Who it may be forLung Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Dec 13, 2019 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?University of Wisconsin, Madison

Study sponsor

Study overview

What this study is about

Purpose: Prevention
Study type: Interventional
Phase: Phase 1
Sponsor: University of Wisconsin, Madison
Interventions being studied: Radiation: radiation therapy (radiotherapy)

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Radiation therapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Thoracic neoplasm requiring at lest 60 Gy conventional radiotherapy

Reasons someone may not be able to joinExclusion criteria

Prior bleomycin or gemcitabine chemotherapy
Prior thoracic radiotherapy

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

University of Wisconsin Hospital and ClinicsMadison, Wisconsin

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 13, 2019. Always confirm current availability with the study team.

View original record ↗